Literature DB >> 24577137

Adverse socioeconomic position during the life course is associated with multiple sclerosis.

Farren B S Briggs1, Brigid S Acuña2, Ling Shen2, Kalliope H Bellesis2, Patricia P Ramsay1, Hong Quach1, Allan Bernstein3, Catherine Schaefer2, Lisa F Barcellos4.   

Abstract

BACKGROUND: Adverse socioeconomic position (SEP) in childhood and adulthood is associated with a proinflammatory phenotype, and therefore an important exposure to consider for multiple sclerosis (MS), a complex neuroinflammatory autoimmune disease. The objective was to determine whether SEP over the life course confers increased susceptibility to MS.
METHODS: 1643 white, non-Hispanic MS case and control members recruited from the Kaiser Permanente Medical Care Plan, Northern California Region, for which comprehensive genetic, clinical and environmental exposure data have been collected were studied. Logistic regression models investigated measures of childhood and adulthood SEP, and accounted for effects due to established MS risk factors, including HLA-DRB1*15:01 allele carrier status, smoking history, history of infectious mononucleosis, family history of MS and body size.
RESULTS: Multiple measures of childhood and adulthood SEP were significantly associated with risk of MS, including parents renting versus owning a home at age 10: OR=1.48, 95% CI 1.09 to 2.02, p=0.013; less than a college education versus at least a college education based on parental household: OR=1.28, 95% CI 1.01 to 1.63, p=0.041; low versus high life course SEP: OR=1.50, 95% CI 1.09 to 2.05, p=0.012; and low versus high social mobility: OR=1.74, 95% CI 1.27 to 2.39, p=5.7×10(-4).
CONCLUSIONS: Results derived from a population-representative case-control study provide support for the role of adverse SEP in MS susceptibility and add to the growing evidence linking lower SEP to poorer health outcomes. Both genetic and environmental contributions to chronic conditions are important and must be characterised to fully understand MS aetiology. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Epidemiology; Lifecourse / Childhood Circumstances; Multiple Sclerosis; Social Epidemiology; Social and life-course epidemiology

Mesh:

Year:  2014        PMID: 24577137     DOI: 10.1136/jech-2013-203184

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  16 in total

1.  Feasibility study for remote assessment of cognitive function in multiple sclerosis.

Authors:  Michaela F George; Calliope B Holingue; Farren B S Briggs; Xiaorong Shao; Kalliope H Bellesis; Rachel A Whitmer; Catherine Schaefer; Ralph Hb Benedict; Lisa F Barcellos
Journal:  J Neurol Neuromedicine       Date:  2016

2.  The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis.

Authors:  Devi Sai Sri Kavya Boorgu; Shruthi Venkatesh; Chirag M Lakhani; Elizabeth Walker; Ines M Aguerre; Claire Riley; Chirag J Patel; Philip L De Jager; Zongqi Xia
Journal:  Mult Scler Relat Disord       Date:  2022-06-24       Impact factor: 4.808

3.  Maternal and Perinatal Exposures Are Associated With Risk for Pediatric-Onset Multiple Sclerosis.

Authors:  Jennifer S Graves; Tanuja Chitnis; Bianca Weinstock-Guttman; Jennifer Rubin; Aaron S Zelikovitch; Bardia Nourbakhsh; Timothy Simmons; Michael Waltz; T Charles Casper; Emmanuelle Waubant
Journal:  Pediatrics       Date:  2017-04       Impact factor: 7.124

4.  Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study.

Authors:  Kjetil Bjørnevik; Trond Riise; Marianna Cortese; Trygve Holmøy; Margitta T Kampman; Sandra Magalhaes; Kjell-Morten Myhr; Christina Wolfson; Maura Pugliatti
Journal:  Mult Scler       Date:  2015-05-26       Impact factor: 6.312

5.  Obesity and Multiple Sclerosis Susceptibility: A Review.

Authors:  Milena A Gianfrancesco; Lisa F Barcellos
Journal:  J Neurol Neuromedicine       Date:  2016

6.  Life course epidemiology: Modeling educational attainment with administrative data.

Authors:  Leslie L Roos; Elizabeth Wall-Wieler
Journal:  PLoS One       Date:  2017-12-27       Impact factor: 3.240

7.  High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies.

Authors:  A K Hedström; E M Mowry; M A Gianfrancesco; X Shao; C A Schaefer; L Shen; T Olsson; L F Barcellos; L Alfredsson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-03-03       Impact factor: 10.154

8.  Characteristics in childhood and adolescence associated with future multiple sclerosis risk in men: cohort study.

Authors:  M Gunnarsson; R Udumyan; S Bahmanyar; Y Nilsagård; S Montgomery
Journal:  Eur J Neurol       Date:  2015-04-27       Impact factor: 6.089

9.  Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

Authors:  Michaela F George; Farren B S Briggs; Xiaorong Shao; Milena A Gianfrancesco; Ingrid Kockum; Hanne F Harbo; Elisabeth G Celius; Steffan D Bos; Anna Hedström; Ling Shen; Allan Bernstein; Lars Alfredsson; Jan Hillert; Tomas Olsson; Nikolaos A Patsopoulos; Philip L De Jager; Annette B Oturai; Helle B Søndergaard; Finn Sellebjerg; Per S Sorensen; Refujia Gomez; Stacy J Caillier; Bruce A C Cree; Jorge R Oksenberg; Stephen L Hauser; Sandra D'Alfonso; Maurizio A Leone; Filippo Martinelli Boneschi; Melissa Sorosina; Ingrid van der Mei; Bruce V Taylor; Yuan Zhou; Catherine Schaefer; Lisa F Barcellos
Journal:  Neurol Genet       Date:  2016-08-04

10.  Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk.

Authors:  Brooke Rhead; Maria Bäärnhielm; Milena Gianfrancesco; Amanda Mok; Xiaorong Shao; Hong Quach; Ling Shen; Catherine Schaefer; Jenny Link; Alexandra Gyllenberg; Anna Karin Hedström; Tomas Olsson; Jan Hillert; Ingrid Kockum; M Maria Glymour; Lars Alfredsson; Lisa F Barcellos
Journal:  Neurol Genet       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.